glp1Injectable

Mazdutide

Also known as: IBI362, GLP-1/glucagon

Chemical structure of Mazdutide (PubChem CID 167312357)
Structure via PubChem
Half-life
120 h
Typical timing
any
Food rule
either
Default unit
mg

Studied for

Overview

Mazdutide, also known by its investigational code IBI362, is an innovative synthetic peptide that acts as a dual agonist on both glucagon-like peptide-1 (GLP-1) and glucagon receptors. This compound is currently under development primarily for the treatment of obesity and related metabolic disorders. By engaging both of these critical receptors, Mazdutide aims to leverage the distinct metabolic effects of each while potentially offering a more comprehensive approach to managing energy balance, glucose homeostasis, and body weight. GLP-1 receptor agonists are a well-established class of drugs known for their ability to enhance insulin secretion in a glucose-dependent manner, suppress glucagon release, slow gastric emptying, and promote satiety, all of which contribute to glycemic control and weight reduction. Glucagon, traditionally associated with raising blood glucose, also plays a role in energy expenditure and lipid metabolism, particularly through its effects on the liver and adipose tissue. By combining these two mechanisms, Mazdutide is hypothesized to induce synergistic effects that could lead to greater improvements in weight loss and metabolic parameters than GLP-1 agonism alone. Mazdutide is administered as an injectable medication. Its development reflects a growing interest in multi-agonist approaches to tackle complex metabolic diseases, moving beyond single-receptor targeting to optimize therapeutic outcomes. Clinical trials are ongoing to fully characterize its efficacy, safety, and optimal use in patient populations with obesity and type 2 diabetes.

Deep dive

Tap a section to expand.

Known interactions

  • Category rule: glp1 × supplement
    Note

    GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.

    Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider.

Frequently asked

Sources referenced

["ClinicalTrials.gov", "PubChem", "Pharmaceutical company press releases and investor reports (ongoing clinical trials)", "Scientific conference abstracts (e.g., American Diabetes Association, Obesity Week)"]

Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.

Related compounds

Others in the glp1 category or studied for the same goals.

Related benefits

Other compounds studied for the same benefits as Mazdutide.

Continue exploring

See every compound Stackwise catalogues for these goals.

Track Mazdutide in Stackwise

Add it to your stack. We'll schedule doses, check interactions against everything else you take, and remind you at the right time.

Sign up free →